{"id":"trastuzumab-deruxtecan-t-dxd","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-30%","effect":"Neutropenia"},{"rate":"5-20%","effect":"Thrombocytopenia"},{"rate":"5-20%","effect":"Anemia"},{"rate":"5-20%","effect":"Increased alanine aminotransferase"},{"rate":"5-20%","effect":"Increased aspartate aminotransferase"},{"rate":"5-20%","effect":"Increased gamma-glutamyltransferase"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"T-DXd works by binding to the HER2 protein on the surface of cancer cells, which then internalizes the conjugate and releases the DNA crosslinking agent, causing DNA damage and cell death. This mechanism is specific to cancer cells that overexpress HER2, making it a targeted therapy for HER2-positive cancers.","oneSentence":"Trastuzumab deruxtecan (T-DXd) is a HER2-targeting antibody-drug conjugate that delivers a DNA crosslinking agent to cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:56.626Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Locally advanced or metastatic HER2-positive breast cancer"},{"name":"Locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma"}]},"trialDetails":[{"nctId":"NCT04704661","phase":"PHASE1","title":"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-09","conditions":"Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma","enrollment":51},{"nctId":"NCT04585958","phase":"PHASE1","title":"Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-21","conditions":"Metastatic Malignant Solid Neoplasm, Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma, Unresectable Malignant Solid Neoplasm","enrollment":55},{"nctId":"NCT07137416","phase":"PHASE1","title":"Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-10-05","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma","enrollment":36},{"nctId":"NCT05372614","phase":"PHASE1","title":"Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-10-05","conditions":"Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm","enrollment":33},{"nctId":"NCT07371585","phase":"PHASE2","title":"Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management","status":"RECRUITING","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2026-02-18","conditions":"Breast Cancer Stage IV","enrollment":300},{"nctId":"NCT07012031","phase":"PHASE1, PHASE2","title":"Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-07","conditions":"Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8","enrollment":37},{"nctId":"NCT04616560","phase":"PHASE2","title":"Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-03-08","conditions":"Osteosarcoma, Recurrent Osteosarcoma","enrollment":77},{"nctId":"NCT04482309","phase":"PHASE2","title":"A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-08-18","conditions":"Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer","enrollment":477},{"nctId":"NCT07195344","phase":"PHASE4","title":"Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.","status":"RECRUITING","sponsor":"Institut Claudius Regaud","startDate":"2025-10-15","conditions":"Locally Advanced or Metastatic Breast Cancers","enrollment":210},{"nctId":"NCT07060807","phase":"PHASE3","title":"A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-21","conditions":"Breast Neoplasms","enrollment":1000},{"nctId":"NCT06311214","phase":"PHASE2","title":"Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-03-18","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm","enrollment":500},{"nctId":"NCT04639219","phase":"PHASE2","title":"A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-12-30","conditions":"Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast","enrollment":102},{"nctId":"NCT04539938","phase":"PHASE2","title":"A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer","status":"COMPLETED","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2020-12-01","conditions":"HER2 Positive Breast Cancer","enrollment":70},{"nctId":"NCT07015697","phase":"PHASE1","title":"A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2025-07-17","conditions":"Recurrent or Metastatic Solid Tumors","enrollment":76},{"nctId":"NCT06467357","phase":"PHASE3","title":"Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-12","conditions":"Biliary Tract Cancer","enrollment":620},{"nctId":"NCT07294508","phase":"PHASE2, PHASE3","title":"A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-02-27","conditions":"HER2 + Breast Cancer","enrollment":706},{"nctId":"NCT06324357","phase":"PHASE1, PHASE2","title":"Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2024-06-03","conditions":"Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":768},{"nctId":"NCT06973161","phase":"","title":"ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-06-10","conditions":"Bladder Cancer, Biliary Tract Cancer, Cervical Cancer","enrollment":105},{"nctId":"NCT06731478","phase":"PHASE3","title":"Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2025-02-27","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":726},{"nctId":"NCT06364410","phase":"PHASE1","title":"Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-02-03","conditions":"Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8","enrollment":48},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT06731803","phase":"PHASE1, PHASE2","title":"Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma","status":"RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2025-03-25","conditions":"Esophagogastric Adenocarcinoma","enrollment":36},{"nctId":"NCT06989112","phase":"PHASE3","title":"DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-27","conditions":"Endometrial Cancer","enrollment":600},{"nctId":"NCT05417594","phase":"PHASE1, PHASE2","title":"Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-06-24","conditions":"Advanced Solid Malignancies","enrollment":695},{"nctId":"NCT07459673","phase":"PHASE2","title":"HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2026-03-04","conditions":"Breast Cancer, HER2-positive Breast Cancer, Breast Cancer Stage IV","enrollment":60},{"nctId":"NCT05744375","phase":"PHASE2","title":"Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab","status":"TERMINATED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2023-09-28","conditions":"Locally Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":2},{"nctId":"NCT07465172","phase":"NA","title":"GDF-15 and Its Relationship With Treatment-related ADverse Events in Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Breast Cancer Trials, Australia and New Zealand","startDate":"2026-03","conditions":"Breast Cancer","enrollment":150},{"nctId":"NCT07069712","phase":"PHASE2","title":"A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-07-17","conditions":"Gastroesophageal Adenocarcinoma","enrollment":100},{"nctId":"NCT06048718","phase":"PHASE2","title":"T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedSIR","startDate":"2024-06-05","conditions":"Breast Cancer, Metastatic Breast Cancer","enrollment":28},{"nctId":"NCT06764875","phase":"PHASE3","title":"A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-01","conditions":"HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":840},{"nctId":"NCT07454668","phase":"PHASE1","title":"Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases","status":"NOT_YET_RECRUITING","sponsor":"Baptist Health South Florida","startDate":"2026-06","conditions":"Breast Cancer, HER2-positive Breast Cancer, Brain Metastases","enrollment":20},{"nctId":"NCT06819007","phase":"PHASE3","title":"Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2025-03-19","conditions":"Ovarian Cancer","enrollment":582},{"nctId":"NCT04494425","phase":"PHASE3","title":"Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-07-24","conditions":"Advanced or Metastatic Breast Cancer","enrollment":866},{"nctId":"NCT07446452","phase":"PHASE2","title":"Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-01-01","conditions":"HER2-low Breast Cancer","enrollment":37},{"nctId":"NCT06486883","phase":"PHASE2","title":"Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype","status":"RECRUITING","sponsor":"MedSIR","startDate":"2025-06-30","conditions":"Advanced Breast Cancer, Advanced Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma","enrollment":200},{"nctId":"NCT05573893","phase":"","title":"PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-09-12","conditions":"Breast Neoplasms, Breast Cancer, Neoplasm Metastasis","enrollment":800},{"nctId":"NCT06750484","phase":"PHASE2","title":"Trial of Trastuzumab Deruxtecan in Previously Treated HER2","status":"RECRUITING","sponsor":"Yale University","startDate":"2025-06-20","conditions":"Breast Cancer Metastatic","enrollment":40},{"nctId":"NCT04294628","phase":"PHASE1","title":"Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-01","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm","enrollment":62},{"nctId":"NCT03523585","phase":"PHASE3","title":"DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2018-08-01","conditions":"Breast Cancer","enrollment":608},{"nctId":"NCT07124000","phase":"","title":"DESTINY-PANTUMOUR04","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-09-18","conditions":"Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer","enrollment":100},{"nctId":"NCT05113251","phase":"PHASE3","title":"Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-10-25","conditions":"Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer","enrollment":927},{"nctId":"NCT07428044","phase":"PHASE2","title":"A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2026-02-13","conditions":"Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer Stage II, Non-Small Cell Lung Cancer Stage IIIA","enrollment":14},{"nctId":"NCT06058988","phase":"PHASE2","title":"Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-09-22","conditions":"Brain Cancer, Glioblastoma, Metastatic Cancer","enrollment":30},{"nctId":"NCT04379596","phase":"PHASE2","title":"Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2020-06-03","conditions":"Gastric Cancer","enrollment":450},{"nctId":"NCT04784715","phase":"PHASE3","title":"Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-04-26","conditions":"Breast Cancer; HER2-positive; Metastatic","enrollment":1157},{"nctId":"NCT04644068","phase":"PHASE1, PHASE2","title":"Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-11-12","conditions":"Ovarian Cancer, Breast Cancer, Pancreatic Cancer","enrollment":702},{"nctId":"NCT07416253","phase":"PHASE2","title":"Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2026-03","conditions":"Breast Cancer","enrollment":68},{"nctId":"NCT07407465","phase":"PHASE2","title":"Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2025-10-20","conditions":"Colorectal Cancer, Colorectal Adenocarcinoma, Rectal Adenocarcinoma","enrollment":42},{"nctId":"NCT05945732","phase":"","title":"DESTINY Breast Respond HER2-low Europe","status":"RECRUITING","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2023-10-24","conditions":"Unresectable Breast Cancer, Metastatic Breast Cancer, HER2-low Expressing Breast Cancer","enrollment":1155},{"nctId":"NCT05993234","phase":"","title":"A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)","status":"RECRUITING","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2023-12-05","conditions":"HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma","enrollment":257},{"nctId":"NCT06585969","phase":"PHASE3","title":"A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer","status":"WITHDRAWN","sponsor":"Danish Breast Cancer Cooperative Group","startDate":"2026-01-01","conditions":"Metastatic Breast Cancer, ER-positive Breast Cancer, Luminal B","enrollment":""},{"nctId":"NCT04739761","phase":"PHASE3","title":"A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-06-22","conditions":"Breast Cancer","enrollment":506},{"nctId":"NCT06435429","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Jazz Pharmaceuticals","startDate":"2024-08-13","conditions":"Metastatic HER2-positive Breast Cancer","enrollment":550},{"nctId":"NCT06250777","phase":"PHASE2","title":"Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases","status":"ENROLLING_BY_INVITATION","sponsor":"Yonsei University","startDate":"2024-07-11","conditions":"Non Small Cell Lung Cancer","enrollment":27},{"nctId":"NCT05950945","phase":"PHASE3","title":"Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2023-12-30","conditions":"Breast Cancer","enrollment":250},{"nctId":"NCT07022483","phase":"PHASE3","title":"Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2025-09-30","conditions":"Endometrial Cancer","enrollment":710},{"nctId":"NCT06244485","phase":"PHASE1","title":"A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2024-02-16","conditions":"Advanced Solid Tumor","enrollment":210},{"nctId":"NCT07368543","phase":"PHASE2","title":"Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-01-16","conditions":"Metastatic Breast Cancer","enrollment":216},{"nctId":"NCT04744831","phase":"PHASE2","title":"Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2021-03-05","conditions":"Advanced Colorectal Cancer","enrollment":122},{"nctId":"NCT05408845","phase":"PHASE2","title":"Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-03-03","conditions":"Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8","enrollment":146},{"nctId":"NCT07340164","phase":"PHASE2","title":"Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2025-12-30","conditions":"Ovarian Cancer, Ovarian Carcinoma, Recurrent, Ovarian Cancer Metastatic Recurrent","enrollment":116},{"nctId":"NCT04704934","phase":"PHASE3","title":"Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2021-05-21","conditions":"Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":490},{"nctId":"NCT06210776","phase":"","title":"A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2024-01-15","conditions":"HER2-positive Breast Cancer, HER2-low Breast Cancer, Breast Cancer","enrollment":800},{"nctId":"NCT06961331","phase":"","title":"Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2025-05-07","conditions":"Metastatic HER2+ Advanced Breast Cancer","enrollment":86},{"nctId":"NCT06899126","phase":"PHASE3","title":"Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2025-10-24","conditions":"Non-small Cell Lung Cancer","enrollment":686},{"nctId":"NCT07049133","phase":"","title":"Toxicity Markers to Trastuzumab-Deruxtecan (T-DXd) In Patients With Advanced Breast Cancer","status":"RECRUITING","sponsor":"European Institute of Oncology","startDate":"2025-07-31","conditions":"Metastatic Breast Cancer","enrollment":84},{"nctId":"NCT05048797","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-10-28","conditions":"Locally Advanced or Metastatic Non-Small Cell Lung Cancer","enrollment":454},{"nctId":"NCT07294430","phase":"PHASE2","title":"Antibody-based PET Imaging and Treatment Response in Breast Cancer Treated With an Antibody-drug Conjugate.","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2025-12-31","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":30},{"nctId":"NCT04556773","phase":"PHASE1","title":"A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-12-17","conditions":"Metastatic Breast Cancer","enrollment":138},{"nctId":"NCT07281001","phase":"NA","title":"A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients","status":"RECRUITING","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2025-12","conditions":"HER2-positive Breast Cancer, Trastuzumab Deruxtecan","enrollment":60},{"nctId":"NCT06085755","phase":"PHASE1, PHASE2","title":"Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Jeeyun Lee","startDate":"2024-09-30","conditions":"Stomach Neoplasm","enrollment":61},{"nctId":"NCT06630130","phase":"PHASE2","title":"Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer","status":"RECRUITING","sponsor":"Jeeyun Lee","startDate":"2025-01-22","conditions":"Stomach Neoplasms","enrollment":50},{"nctId":"NCT04538742","phase":"PHASE1, PHASE2","title":"A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-12-28","conditions":"Metastatic Breast Cancer","enrollment":245},{"nctId":"NCT07259226","phase":"PHASE2","title":"Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-11-14","conditions":"Advanced Breast Cancer, Advanced Gastric Cancer, Advanced Urothelial Cancer","enrollment":400},{"nctId":"NCT06663787","phase":"","title":"Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Who Achieved Durable Response by Anti-HER2 Treatment (HER2 CR)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nagoya City University","startDate":"2024-04-01","conditions":"Breast Cancer, Metastatic, HER2 + Breast Cancer","enrollment":50},{"nctId":"NCT05982678","phase":"PHASE2","title":"Basket Study for Oligo-metastatic Breast Cancer","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2024-05-02","conditions":"HER2-positive Breast Cancer","enrollment":72},{"nctId":"NCT05088395","phase":"NA","title":"Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4","status":"RECRUITING","sponsor":"Institut Curie","startDate":"2022-05-19","conditions":"Cancer","enrollment":2050},{"nctId":"NCT05704829","phase":"PHASE2","title":"NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"West German Study Group","startDate":"2024-02-05","conditions":"HER2-positive Early Breast Cancer","enrollment":402},{"nctId":"NCT04686305","phase":"PHASE1","title":"Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2021-03-09","conditions":"Locally Advanced or Metastatic Non-Small Cell Lung Cancer","enrollment":244},{"nctId":"NCT07198724","phase":"PHASE1, PHASE2","title":"ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sarah Sammons, MD","startDate":"2026-03","conditions":"Metastatic Breast Cancer, HER2 Low Breast Carcinoma, HER2-negative Breast Cancer","enrollment":65},{"nctId":"NCT03334617","phase":"PHASE2","title":"Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-12-18","conditions":"Non-Small Cell Lung Cancer","enrollment":528},{"nctId":"NCT06533826","phase":"PHASE2","title":"TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd","status":"RECRUITING","sponsor":"Ana C Garrido-Castro, MD","startDate":"2024-10-29","conditions":"Breast Cancer, HER2-low Breast Cancer, Metastatic Breast Cancer","enrollment":357},{"nctId":"NCT06271837","phase":"PHASE2","title":"A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-02-18","conditions":"Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)","enrollment":175},{"nctId":"NCT03529110","phase":"PHASE3","title":"DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2018-08-09","conditions":"Breast Cancer","enrollment":524},{"nctId":"NCT06386263","phase":"","title":"HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-04-22","conditions":"Unresectable Breast Cancer, Metastatic Breast Cancer, HER2-low Expressing Breast Cancer","enrollment":22},{"nctId":"NCT06174987","phase":"PHASE3","title":"A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2024-01-05","conditions":"Advanced Cancer, Metastatic Cancer","enrollment":50},{"nctId":"NCT06680596","phase":"PHASE2","title":"Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy","status":"ENROLLING_BY_INVITATION","sponsor":"UNICANCER","startDate":"2025-07-30","conditions":"Breast Cancer Metastatic, Breast Cancer Stage IV","enrollment":80},{"nctId":"NCT07130344","phase":"NA","title":"PERCIST Evaluation of Trastuzumab Deruxtecan in the Treatment of HER2 Low Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Centre Paul Strauss","startDate":"2025-09","conditions":"Metastatic Breast Cancer, HER 2 Low-expressing Breast Cancer","enrollment":262},{"nctId":"NCT04257162","phase":"NA","title":"HER2-PREDICT: Translational Study of Tumor Samples From Patients Treated With Trastuzumab Deruxtecan (T-DXd; DS-8201a)","status":"ACTIVE_NOT_RECRUITING","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2019-12-13","conditions":"Metastatic Cancer","enrollment":180},{"nctId":"NCT07086768","phase":"PHASE1","title":"Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Lei Zheng","startDate":"2026-01-01","conditions":"Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor","enrollment":57},{"nctId":"NCT07152782","phase":"PHASE2","title":"T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-11","conditions":"Breast Cancer With Brain Metastasis, HER2-positive Breast Cancer","enrollment":202},{"nctId":"NCT07151586","phase":"PHASE2","title":"Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2025-10","conditions":"Triple Negative Breast Neoplasms, Neoplasm Metastasis, HER 2 Low-expressing Breast Cancer","enrollment":260},{"nctId":"NCT07150208","phase":"PHASE2","title":"T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-09","conditions":"Breast Cancer With Brain Metastasis, HER2-low Expressing Breast Cancer","enrollment":140},{"nctId":"NCT05900206","phase":"PHASE2","title":"Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Karolinska University Hospital","startDate":"2023-10-26","conditions":"Breast Cancer","enrollment":370},{"nctId":"NCT05246514","phase":"PHASE2","title":"A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-07-13","conditions":"HER2-mutant Non-Small Cell Lung Cancer","enrollment":72},{"nctId":"NCT07134153","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-04-18","conditions":"Breast Cancer","enrollment":139},{"nctId":"NCT05678205","phase":"PHASE1, PHASE2","title":"A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors","status":"WITHDRAWN","sponsor":"Artiva Biotherapeutics, Inc.","startDate":"2023-08-01","conditions":"Breast Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":""},{"nctId":"NCT06172127","phase":"PHASE2","title":"PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"MedSIR","startDate":"2024-07-22","conditions":"HER2-positive Breast Cancer","enrollment":165},{"nctId":"NCT06610825","phase":"PHASE2","title":"Castrate Resistant Prostate Cancer Enhertu Therapy","status":"RECRUITING","sponsor":"Washington D.C. Veterans Affairs Medical Center","startDate":"2025-03-05","conditions":"Prostate Cancer Metastatic, Prostate Cancer, CRPC","enrollment":60},{"nctId":"NCT07073755","phase":"","title":"Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd","status":"RECRUITING","sponsor":"Hunan Cancer Hospital","startDate":"2023-01-01","conditions":"Metastatic Breast Cancer, Drug Resistance, Hormone Receptor-Positive Breast Cancer","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":38,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ENHERTU®","Enhertu","DS-8201a","DS8201"],"phase":"phase_3","status":"active","brandName":"trastuzumab deruxtecan (T-DXd)","genericName":"trastuzumab deruxtecan (T-DXd)","companyName":"GI Innovation, Inc.","companyId":"gi-innovation-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Trastuzumab deruxtecan (T-DXd) is a HER2-targeting antibody-drug conjugate that delivers a DNA crosslinking agent to cancer cells. Used for Locally advanced or metastatic HER2-positive breast cancer, Locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}